A subsidiary of Granules India, Granules USA said that it has entered into an agreement for marketing generic version of OTC omeprazole and sodium bicarbonate in North American market with Par Pharmaceutical.

The company is expecting the US Food and Drug Administration’s approvals by July this year.

Krishna Prasad Chigurupati, CMD Granules India Ltd said that “…through this exclusive agreement with Par Pharmaceutical, we can strengthen our OTC product basket and widen our offerings in the North American store brand market for meeting retailers’ and consumers’ desire for competitive market choices and alternatives.”

Read EquityPandit’s Technical Analysis of Indian Stock Market